IL17A and psoriasis: Besides, psoriasis positively responds to the treatmentinvolving IL-17 antibodies (e.g. secukinumab, ixekizumab, and brodalumab) thattargets the IL-17 cytokine pathway to alleviate the inflammatory response [78–80].